Overview Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis Status: Completed Trial end date: 2022-10-21 Target enrollment: Participant gender: Summary The primary objective of the study was to evaluate the safety and tolerability of 611 in chinese adults with moderate to severe atopic dermatitis. Phase: Phase 1/Phase 2 Details Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.